Bell John K 4
4 · DelMar Pharmaceuticals, Inc. · Filed Nov 17, 2017
Insider Transaction Report
Form 4
Bell John K
Director
Transactions
- Purchase
Common Stock
2017-11-15$0.81/sh+1,871$1,516→ 76,890 total(indirect: See footnote) - Purchase
Common Stock
2017-11-16$0.81/sh+18,129$14,684→ 95,019 total(indirect: See footnote)
Footnotes (3)
- [F1]This transaction was executed in multiple trades at prices ranging from $0.7997 to $0.84. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $0.8086 to $0.81. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request, to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]Shares are held by Onbelay Capital Inc.